Neoprobe Interviewed by WallSt.net; CFO Provides Business Update.DUBLIN, Ohio -- Neoprobe Corporation (OTCBB OTCBB
See OTC Bulletin Board (OTCBB). :NEOP NEOP Neoprobe Corporation (stock symbol)
NEOP Near Earth Object Program
NEOP New England Order of Protection
NEOP Nuclear Explosive Operating Procedure ), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced that the Company is presently featured in an online interview at www.WallSt.net. CFO See Chief Financial Officer. Brent Larson discusses the Company's biomedical bi·o·med·i·cal
1. Of or relating to biomedicine.
2. Of, relating to, or involving biological, medical, and physical sciences. product offerings and development activities as well as other matters impacting the future performance of the company.
The Neoprobe Corporation interview is available at http://www.WallSt.net. If you are not already a wallst.net subscriber, you may sign up for free by clicking on the "Sign me up - FREE!" button at the top of the page. After establishing your user ID and password, click on the "Submit" button at the top of the page. This will register you and send you back to the WallSt.net home page. You may access the interview by clicking on the "Interview" button on the toolbar A row or column of on-screen buttons used to activate functions in the application. Many toolbars are customizable, letting you add and delete buttons as required. Toolbars may be fixed in position or may float, which means they can be dragged to a more convenient location in the near the top of the page and entering the trading symbol Trading symbol
See: Ticker symbol "NEOP" in the Search Archive dialog box mid-way down the page.
Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neo2000(R) line of gamma detection systems that are widely used by cancer surgeons and is commercializing the Quantix(R) line of blood flow measurement products developed by its subsidiary, Cardiosonix Ltd. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical radiopharmaceutical /ra·dio·phar·ma·ceu·ti·cal/ (-fahr?mah-soo´ti-k'l) a radioactive pharmaceutical, nuclide, or other chemical used for diagnostic or therapeutic purposes. agents including Lymphoseek(TM) and RIGScan(R) CR. Neoprobe's subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe's strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. www.neoprobe.com